San Diego, California, USA - November 13-16, 2024
SeekIn Inc., a leader in blood-based cancer early detection and monitoring technology, unveiled two groundbreaking innovations at the AACR Liquid Biopsy Conference, ushering in a new era of cancer screening and monitoring.
1. Two-Step Multi-Cancer Screening Strategy
The new technologies in cancer screening currently face challenges such as high false-positive rates and costly procedures. SeekIn has developed a two-step screening strategy that significantly reduces false positives and alleviates the financial burden of population-wide screening, offering more affordable Multi-Cancer Early Detection (MCED).
In two-step approach, the initial screening is conducted using OncoSeek® (blood-based low-cost multi-cancer early detection test), followed by confirmation with SeekInCare® (blood-based pan-cancer early detection test) for positive cases. In a study involving 1197 individuals (617 cancer patients and 580 non-cancer individuals), the approach dramatically decreased the false-positive rate from 9.0% to 0.7% (a 12.9-fold reduction). In a simulation of screening 5 million individuals, compared to NGS-based MCED test, the approach reduced total screening costs by 6.6 times and costs per cancer patient by 5.2 times.
2. SeekInClarity®: blood-based pan-cancer treatment response monitoring test
While traditional imaging techniques are essential for monitoring treatment efficacy, it sometimes falls short in accurately measuring tumor changes, differentiating between treatment progress and pseudo-progression, and can be subject to interpretation bias, leading to delayed treatment decisions.
SeekInClarity® offers a breakthrough in tumor treatment monitoring with a multi-omics approach that is both cost-effective and tumor-naive. This advanced assay delivers a more precise evaluation of treatment responses, minimizes the risk of misjudgment, and speeds up the assessment process. By offering timely and objective data, SeekInClarity® empowers clinicians with the information they need to make informed, swift decisions.
In a prospective study of 114 lymphoma patients, SeekInClarity® was compared with imaging assessments to evaluate treatment effects:
- The study revealed that at baseline, 74.1% of lymphoma patients had a positive MTB (molecular tumor burden) (MTB ≥ 2), with a specificity of up to 95.2%.
- Survival analysis further revealed that MTB-positive patients had significantly shorter progression-free survival (PFS) compared with MTB-negative patients, both at baseline and after 2 cycles of treatment.
- After two cycles of treatment, patients with MTB-positive status were more than 5.2 times more likely to develop disease progression (PD) than MTB-negative patients, outperforming existing clinical biomarkers lactate dehydrogenase (LDH) and β2-microglobulin (B2M).
About AACR Liquid Biopsy Conference: AACR Special Conference in Cancer Research: Liquid Biopsy. This conference brings together leaders in the field to share the latest advancements in liquid biopsies encompassing the spectrum from discovery to clinical application. Engage in sessions covering the biology of circulating tumor cells, plasma biomarkers, new technologies, early detection, MRD monitoring, tumor evolution, immunotherapy integration, and computational science.